CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells
about
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancersEZH2 methyltransferase and H3K27 methylation in breast cancerTargeting EZH2 in cancerPolycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic ImplicationsPancreatic Cancer, A Mis-interpreter of the Epigenetic LanguageTumor Suppressor Inactivation in the Pathogenesis of Adult T-Cell LeukemiaP21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancerHistone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiationZodiac: A Comprehensive Depiction of Genetic Interactions in Cancer by Integrating TCGA Data.Long non-coding RNA LUCAT1 is associated with poor prognosis in human non-small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expressionCDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancerRegulation and Role of EZH2 in CancerPolycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2.Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics.The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERKExpression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells.In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancerPolycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage.A genomic approach to predict synergistic combinations for breast cancer treatmentPaternal allelic mutation at the Kcnq1 locus reduces pancreatic β-cell mass by epigenetic modification of Cdkn1cHigh Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.Breast cancer risk and imprinting methylation in blood.EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene.Association of breast cancer risk loci with breast cancer survival.Cbx4: A new guardian of p63's domain of epidermal controlModulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene MutationsMutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia.Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57.HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIsCanonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer.Aberrant promoter CpG methylation and its translational applications in breast cancer.miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A.
P2860
Q24605342-2AFE1530-4238-493E-A8B8-D4B119C5A398Q24633788-D823AFB7-4B58-45C0-BA47-53D71AA12BDEQ26769027-319C5B8B-D430-47D6-A3D1-AE361E2F8A85Q26801380-D0D569A8-8306-4A90-8210-CD2EFBE8B96EQ28079735-A2F3EC4D-887B-4896-A795-C91A579F0681Q28081287-881F9EA1-024C-4427-8364-5575E59D749EQ28294949-41E76922-962C-4001-854E-553AFAFECFEAQ28570956-3DC82D97-F327-459B-A18B-E1DF7F11DBB4Q30947772-95CE03FF-9DF8-408C-8D95-DD6B68B5BFCCQ33709689-0869FA1E-B3B2-4895-8124-364614633F44Q33744679-A7CD566D-ED30-405A-B34E-CA7A13353A62Q34007733-DB1B8808-59D4-435B-9942-4DF0EC519003Q34043370-B8979918-5B55-4242-B55B-3D3E6B623F98Q34134903-857F5269-340C-40E6-AA70-0CF89D3B1646Q34241184-AC5AD333-CA4C-4404-9C20-EFFC75560F48Q34362220-CD6D6B69-4611-4EE6-9E2A-AC201E887858Q34440758-E0D7D294-3239-48B5-8787-62CEB8C3298AQ34496410-7C6D4266-7995-41FD-ABA0-5EF8F33DEDCBQ34571374-ADDE099B-A420-4DE3-8F9D-738ED4078B19Q34666213-616F8C47-1841-46BB-B5BC-29BEFD6FDA95Q35020435-9C033447-D52C-4CD6-A4DD-770DE56F2B09Q35116862-796A8FC7-64D1-4F32-8713-8F961880E4DEQ35302120-300F5C7E-5057-4781-B3D3-A96019C202FCQ35670293-588E6844-D30A-4521-9E5A-25E10311DF19Q35845810-18E95C34-A27A-4FFD-88D0-9B4D9D960A51Q35918810-9CA374EB-DBDC-4A4E-93B8-8E43C204F5ECQ35921549-6A9C220C-CA5A-40E3-BF30-6460ACA8C0F1Q36027913-0B4D99FA-8E61-481F-9F5A-F7404F726C08Q36037967-9142640D-47AF-4DBF-87E0-767BB6665E24Q36191018-061F523F-2643-4761-9424-57EE5E76D485Q36428050-13143336-E6AC-4E08-9194-651AB9085205Q36535735-829B9D0C-72A8-440A-AB91-9AE3934ADFB2Q36583644-AED2EC71-6A20-413B-9558-0CF47C9FF9E8Q36847513-9D2590AB-FC7B-4EB2-A0EB-739FBF8419DAQ37065194-8AD1B117-F8AC-48F6-8109-218C2B20191EQ37089496-CA75E424-40C3-49CA-A6F7-AF626F202144Q37268975-41315A7A-CEF0-4369-BD2A-87B9688B4A46Q37350954-A87F27F3-777B-40DD-8676-136FD3FE853BQ37354053-18B5F0A4-7DCA-4322-9353-DEE71CC1F508Q37393628-0AFBDBE4-CD38-4FDA-BDCC-59C8252172A0
P2860
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
CDKN1C (p57) is a direct targe ...... hanisms in breast cancer cells
@ast
CDKN1C (p57) is a direct targe ...... hanisms in breast cancer cells
@en
type
label
CDKN1C (p57) is a direct targe ...... hanisms in breast cancer cells
@ast
CDKN1C (p57) is a direct targe ...... hanisms in breast cancer cells
@en
prefLabel
CDKN1C (p57) is a direct targe ...... hanisms in breast cancer cells
@ast
CDKN1C (p57) is a direct targe ...... hanisms in breast cancer cells
@en
P2093
P2860
P1433
P1476
CDKN1C (p57) is a direct targe ...... hanisms in breast cancer cells
@en
P2093
Meiyee Aau
Patrick Boon Ooi Tan
R K Murthy Karuturi
Rongguang Shao
Xiaojing Yang
P2860
P356
10.1371/JOURNAL.PONE.0005011
P407
P50
P577
2009-04-02T00:00:00Z